Olmesartan medoxomil: As monotherapy and in combination treatment in hypertension

Guido Grassi, Giuseppe Mancia

Research output: Contribution to journalArticlepeer-review


Inadequate blood pressure (BP) control represents one of the major challenges of antihypertensive treatment, being responsible for the elevated cardiovascular morbidity and mortality associated with hypertension. Although guidelines strongly recommend BP control as a primary therapeutic goal, data collected in European and extra-European countries clearly show a poor BP control rate in treated patients with hypertension. Olmesartan medoxomil (olmesartan) is a relatively new antihypertensive agent belonging to the class of angiotensin II type 1 receptor antagonists (angiotensin receptor blockers) whose tolerability and effectiveness in the treatment of essential hypertension have been shown in several trials and clinical studies. This article reviews current findings on the clinical use of olmesartan as an antihypertensive drug given as monotherapy and in combination treatment in both clinical trials and in clinical practice. Olmesartan as monotherapy or in combination drug treatment has shown greater efficacy than placebo, and similar or greater efficacy compared with other classes of antihypertensive agents. Combination therapy with olmesartan also offers significant advantages in BP control over monotherapy with the component agents. Indeed, non-comparator up-titration studies have demonstrated that, as recommended by guidelines, an aggressive treatment algorithm can bring most patients to BP targets. Early-onset antihypertensive therapy appears to provide long-term benefits by reducing the risk of cardiovascular disease, particularly stroke; the antihypertensive effects of olmesartan have been documented from as early as 2 weeks. In clinical practice, olmesartan is effective in both adult and elderly patients and in patients with systolic or diastolic hypertension, or with isolated systolic hypertension. These features, coupled with an excellent tolerability profile, make olmesartan an attractive option for the treatment of patients with hypertension.

Original languageEnglish
Pages (from-to)1-14
Number of pages14
JournalHigh Blood Pressure and Cardiovascular Prevention
Issue number1
Publication statusPublished - 2010


  • Angiotensin II receptor blocker
  • Antihypertensive therapy
  • Blood pressure control
  • Hypertension
  • Olmesartan medoxomil

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine


Dive into the research topics of 'Olmesartan medoxomil: As monotherapy and in combination treatment in hypertension'. Together they form a unique fingerprint.

Cite this